Analysts Maintain Confidence in MoonLake Despite Recent Stock Volatility MoonLake Immunotherapeutics shares dipped 3.1% in recent trading, yet analyst sentiment remains optimistic. The company holds a consensus 'Buy' rating, with price targets averaging $80.50, signaling anticipated upside. Institutional investors are increasing positions, reflecting long-term confidence ahead of key clinical milestones for its lead therapy, sonelokimab.12